Trial · NCT06892054
Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma
NCT06892054, Phase 1, Recruiting, Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma. Trials, record NCT06892054. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06892054
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma
- NCT number
- NCT06892054
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 15 participants, estimated
- Lead sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)
- First posted
- 2025-03-24
- Last updated
- 2026-04-30
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To evaluate the safety and tolerability of sotorasib combined with first-line chemotherapy for locally advanced or metastatic pancreatic adenocarcinoma harboring KRAS p.G12C mutation. | 60 months | Incidence of treatment-emergent adverse events (TEAEs) and related TEAEs (TRAEs) according to CTCAE V5.0. |
| Secondary | To evaluate the progression-free survival assessed by CT or MRI using RECIST 1.1 criteria of first-line chemotherapy combined with sotorasib for advanced pancreatic adenocarcinoma harboring KRAS p.G12C mutation | 60 months | Progression-Free Survival (PFS) is defined as time from the first day of the study treatment (Day 1) until disease progression or death from any cause, whichever occurs first, for all patients, according to the investigator criteria. |
| Secondary | To evaluate the overall survival of first-line chemotherapy combined with sotorasib for advanced pancreatic adenocarcinoma harboring KRAS p.G12C mutation. | 60 months | The overall survival (OS) is defined as time from Day 1 until death from any cause. |
| Secondary | Overall response (OR) | 60 months | The overall response (OR) is defined as the best overall response complete response (CR) or partial response (PR), assessed per RECIST 1.1. |
| Secondary | Disease control (DC) | 60 months | The disease control (DC) is defined as the best overall response of CR or PR or of stable disease. |
| Secondary | Duration of response (DOR) | 60 months | The duration of response (DOR) is defined as the time from onset of response to progression or death due to any reason, whichever occurs earlier. |
| Secondary | Duration of stable disease | 60 months | The duration of stable disease is defined as the time from first disease control to disease progression per RECIST 1.1 criteria or death (due to any cause). For patients with disease control who have not progressed or died at last observation, duration of disease control will be censored at their last evaluable disease assessment date. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06892054
GET https://conductscience.org/api/trials/v1/NCT06892054/registered